Carbamazepine selectively inhibits nAChR and is the first choice anti-epileptic drug for patients with SHE (48); however, approximately one-third of patients develop drug resistance (48), speculating that the drug may only be effective for receptors with gained function. The gene discussed is CHRNA4; the disease is sleep-related hypermotor epilepsy.